Electronic Nudge Letters Do Not Improve Guideline-Directed Medical Therapy in CKD

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 17, 2025.

via HealthDay

TUESDAY, June 17, 2025 -- Neither delivery of electronic nudge letters nor letters to general practice increase uptake of guideline-directed medical therapy (GDMT) among patients with chronic kidney disease (CKD), according to a study published online June 7 in Circulation.

Kristoffer Grundtvig Skaarup, M.D., from Copenhagen University Hospital-Herlev and Gentofte in Denmark, and colleagues examined whether electronic letter-based nudges delivered to individuals with CKD and their general practices could increase GDMT uptake in a nationwide 2-by-2 factorial implementation trial. All Danish adults with a hospital-diagnosis of CKD were randomly assigned to usual care (no letter) or to receive an electronic letter-based nudge on GDMT in CKD (11,394 and 11,223 patients, respectively). In addition, general practices of individuals with CKD were independently randomly assigned to receive no letter or an electronic information letter on GDMT (14,110 patients from 766 practices and 13,959 patients from 774 practices, respectively).

The researchers found that 65.1 and 65.9 percent of patients allocated to the patient-directed nudge and in usual care, respectively, had filled a prescription of a renin-angiotensin system inhibitor (RASi) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) during follow-up. Similarly, 63.9 and 64.4 percent of patients of practices receiving the provider-directed letter and in the usual care group, respectively, filled a prescription for an RASi or SGLT2i. There was no interaction between the interventions.

"These findings represent a null result in the context of large-scale direct-to-patient implementation strategies for GDMT," the authors write. "This trial provides valuable lessons that may help inform future implementation efforts."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-18 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords